What is King Pharmaceuticals's equity method income?

King Pharmaceuticals (KG) reported equity method income of -$1K in Q1 2026.

What does equity method income mean?

The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.

King Pharmaceuticals KG Equity Method Income

Equity Method Income at other companies

Arch Capital GroupACGL

$160M+202%

Greenlight Capital RE, Ltd.GLRE

$33.69M+4.6%

KemperKMPR

$600K+200%

Community Financial SystemCBU

-$326K—

W.R. BerkleyWRB

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's equity method income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's equity method income?: King Pharmaceuticals (KG) reported equity method income of -$1K in Q1 2026.
What does equity method income mean?: The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.